Enhancement of the replication of hepatitis C virus replicons of genotypes 1 to 4 by manipulation of CpG and UpA dinucleotide frequencies and use of cell lines expressing SECL14L2 for antiviral resistance testing

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 2981-2992

  Witteveldt, Jeroen ^a   Martin Gans, Marion ^a   Simmonds, Peter ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CPG DINUCLEOTIDE; DINUCLEOTIDE; NEOMYCIN; SMALL INTERFERING RNA; SOFOSBUVIR; UNCLASSIFIED DRUG; UPA DINUCLEOTIDE; ANTIVIRUS AGENT; DINUCLEOSIDE PHOSPHATE; URIDYLYL-(3'-5')-ADENOSINE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; NONHUMAN; PRIORITY JOURNAL; TRANSIENT TRANSFECTION; VIRUS REPLICATION; CELL LINE; DNA REPLICATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HUMAN; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELL LINE; DINUCLEOSIDE PHOSPHATES; DNA REPLICATION; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; REPLICON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOFOSBUVIR; VIRUS REPLICATION;

EID: 84964923708     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02932-15     Document Type: Article

References (41)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362. http://dx.doi.org/10 .1126/science.2523562.
2. Alter MJ. 1991. Hepatitis C: a sleeping giant? Am J Med 91:112S-115S. http://dx.doi.org/10.1016/0002-9343(91)90354-Z.
3. Bell J, Batey RG, Farrell GC, Crewe EB, Cunningham AL, Byth K. 1990. Hepatitis C virus in intravenous drug users. Med J Aust 153:274-276.
4. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333-1342. http://dx .doi.org/10.1002/hep.26141.
5. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. 2015. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77-87. http://dx.doi.org/10.1002/hep .27259.
6. Hoofnagle JH. 2002. Course and outcome of hepatitis C. Hepatology 36:S21-S29. http://dx.doi.org/10.1053/jhep.2002.36227.
7. Alter MJ. 2007. Epidemiology of hepatitis C virus infection. World J Gastroenterol 13:2436-2441. http://dx.doi.org/10.3748/wjg.v13.i17 .2436.
8. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. 2011. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433-1444. http://dx.doi.org/10.1002 /hep.24641.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982. http://dx.doi.org /10.1056/NEJMoa020047.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965. http://dx.doi.org/10.1016/S0140-6736(01) 06102-5.
11. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. http://dx.doi.org/10.1126 /science.285.5424.110.
12. Krieger N, Lohmann V, Bartenschlager R. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 75:4614-4624. http://dx.doi.org/10.1128/JVI.75.10.4614-4624 .2001.
13. Sumpter R, Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79:2689-2699. http://dx.doi.org/10.1128/JVI.79.5 .2689-2699.2005.
14. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. 2001. Mutations in hepatitisCvirus RNAs conferring cell culture adaptation. J Virol 75:1437-1449. http://dx.doi.org/10.1128/JVI.75.3.1437-1449.2001.
15. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974. http://dx.doi.org /10.1126/science.290.5498.1972.
16. Jiang J, Luo G. 2012. Cell culture-adaptive mutations promote viral protein-protein interactions and morphogenesis of infectious hepatitis C virus. J Virol 86:8987-8997. http://dx.doi.org/10.1128/JVI.00004-12.
17. Atkinson NJ, Witteveldt J, Evans DJ, Simmonds P. 2014. The influence of CpG and UpA dinucleotide frequencies on RNA virus replication and characterization of the innate cellular pathways underlying virus attenuation and enhanced replication. Nucleic Acids Res 42:4527-4545. http://dx .doi.org/10.1093/nar/gku075.
18. Tulloch F, Atkinson NJ, Evans DJ, Ryan MD, Simmonds P. 2014. RNA virus attenuation by codon pair deoptimisation is an artefact of increases in CpG/UpA dinucleotide frequencies. eLife 3:e04531. http://dx.doi.org /10.7554/eLife.04531.
19. Saeed M, Andreo U, Chung HY, Espiritu C, Branch AD, Silva JM, Rice CM. 2015. SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 524:471-475. http://dx.doi.org/10.1038/nature14899.
20. Targett-Adams P, McLauchlan J. 2005. Development and characterization of a transient-replication assay for the genotype 2a hepatitis C virus subgenomic replicon. J Gen Virol 86:3075-3080. http://dx.doi.org/10 .1099/vir.0.81334-0.
21. Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM. 2012. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 56: 5365-5373. http://dx.doi.org/10.1128/AAC.01256-12.
22. Simmonds P. 2012. SSE: a nucleotide and amino acid sequence analysis platform. BMC Res Notes 5:50. http://dx.doi.org/10.1186/1756-0500-5-50.
23. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. http://dx.doi.org /10.1053/j.gastro.2003.09.023.
24. Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, Wakita T. 2005. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 79:592-596. http://dx.doi.org/10.1128/JVI.79.1.592-596.2005.
25. Burns CC, Shaw J, Campagnoli R, Jorba J, Vincent A, Quay J, Kew O. 2006. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J Virol 80: 3259-3272. http://dx.doi.org/10.1128/JVI.80.7.3259-3272.2006.
26. Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, Mueller S. 2008. Virus attenuation by genome-scale changes in codon pair bias. Science 320:1784-1787. http://dx.doi.org/10.1126/science .1155761.
27. Burns CC, Campagnoli R, Shaw J, Vincent A, Jorba J, Kew O. 2009. Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. J Virol 83:9957-9969. http://dx.doi.org/10 .1128/JVI.00508-09.
28. Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA. 2010. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 285:34337-34347. http://dx.doi.org/10.1074 /jbc.M110.161802.
29. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA. 2012. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:3359-3368. http://dx.doi.org/10.1128 /AAC.00054-12.
30. Aghemo A, De Francesco R. 2013. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58:428-438. http://dx .doi.org/10.1002/hep.26371.
31. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA. 2010. Discovery of a beta-d-2=-deoxy-2=-alpha-fluoro-2=-beta-C-methyluridine nucleotide prodrug PSI-7977 for the treatment of hepatitis C virus. J Med Chem 53:7202-7218. http://dx.doi.org/10.1021/jm100863x.
32. Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, Wahling H, Wickstrom K, Hamelink E, Edlund M, Vrang L, Vendeville S, Vande Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K. 2008. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitisCvirus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett 18:4853-4858. http://dx.doi.org /10.1016/j.bmcl.2008.07.088.
33. Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, Vermeiren K, Rosenquist A, Edlund M, Samuelsson B, Vrang L, de Kock H, Wigerinck P, Raboisson P, Simmen K. 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 53:1377-1385. http://dx.doi.org /10.1128/AAC.01058-08.
34. Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG. 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 50:1013-1020. http://dx.doi.org/10 .1128/AAC.50.3.1013-1020.2006.
35. Paolucci S, Fiorina L, Mariani B, Landini V, Gulminetti R, Novati S, Maserati R, Barbarini G, Bruno R, Baldanti F. 2015. Development and persistence of DAA resistance associated mutations in patients failing HCV treatment. J Clin Virol 72:114-118. http://dx.doi.org/10.1016/j.jcv .2015.08.015.
36. Sarrazin C. 26 September 2015. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol http://dx .doi.org/10.1016/j.jhep.2015.09.011.
37. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD. 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 279:17508-17514. http://dx.doi.org /10.1074/jbc.M313020200.
38. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70:28-38. http: //dx.doi.org/10.1016/j.antiviral.2005.12.003.
39. Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, Huang PP, Klein LL, Mo H, Molla A. 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 48:2260-2266. http://dx.doi.org/10.1128 /AAC.48.6.2260-2266.2004.
40. Puigbo P, Bravo IG, Garcia-Vallve S. 2008. CAIcal: a combined set of tools to assess codon usage adaptation. Biol Direct 3:38. http://dx.doi.org /10.1186/1745-6150-3-38.
41. Buchan JR, Aucott LS, Stansfield I. 2006. tRNA properties help shape codon pair preferences in open reading frames. Nucleic Acids Res 34: 1015-1027. http://dx.doi.org/10.1093/nar/gkj488.